Skip to content
ClinCalc Pro
Menu
Carbonic anhydrase inhibitor Pregnancy: Should not be used in pregnancy, especially the first trimester; teratogenic/embryotoxic in animals.

Acetazolamide

Brand names: Diamox

Acetazolamide is a carbonic anhydrase inhibitor used in glaucoma, idiopathic intracranial hypertension, certain epilepsies and the prevention of acute mountain sickness.

Auto-extracted from the source labelling — not yet independently clinician-verified. These values were distilled from the UK SPC (or the US label where noted) but have not had a clinician sign-off. Confirm against the current SmPC before prescribing.

Adult dose

Dose: 250-1000 mg
Route: Oral
Frequency: Per 24 hours, in divided doses for amounts over 250 mg
Glaucoma (simple, acute congestive and secondary): 250-1000 mg per 24 hours. Other indications: abnormal fluid retention / congestive heart failure - diuresis starting dose 250-375 mg once daily in the morning, best on alternate-day or two-days-on/one-day-off regimens; pre-menstrual tension fluid retention 125-375 mg single daily dose. Epilepsy: 250-1000 mg daily in divided doses. Use with caution in the elderly.

Paediatric dose

Route: Oral
Frequency: Daily in divided doses
Max: 750 mg/day
Stated for epilepsy: 8-30 mg/kg in daily divided doses, not to exceed 750 mg/day.

Dose auto-extracted from UK Summary of Product Characteristics (SPC) via the eMC; US FDA prescribing information (openFDA / DailyMed) — cross-check; US labelling may differ from UK — not yet clinician-verified. Always confirm against the product SmPC and your local formulary before prescribing.

Contraindications

  • Hypersensitivity to acetazolamide or any excipient
  • Depressed sodium and/or potassium blood levels
  • Marked kidney and liver disease or dysfunction
  • Suprarenal gland failure
  • Hyperchloraemic acidosis
  • Hepatic cirrhosis (risk of hepatic encephalopathy)
  • Long-term use in chronic non-congestive angle-closure glaucoma
  • Hypersensitivity to sulphonamides

Side effects

  • Paraesthesia (tingling in extremities), dizziness, headache, drowsiness
  • Metabolic acidosis, electrolyte imbalance, thirst
  • Nausea, vomiting, diarrhoea, taste disturbance
  • Blood dyscrasias (thrombocytopenia, leukopenia, aplastic anaemia, agranulocytosis)
  • Transient myopia, choroidal effusion/detachment; skin reactions (urticaria, Stevens-Johnson syndrome, toxic epidermal necrolysis, AGEP)

Interactions

  • May potentiate effects of folic acid antagonists
  • May potentiate hypoglycaemics and oral anticoagulants
  • Concurrent aspirin may cause severe acidosis and increased CNS toxicity

Clinical monograph

How it works

By inhibiting carbonic anhydrase it reduces aqueous humour and cerebrospinal fluid production and promotes renal bicarbonate excretion, producing a mild diuresis and metabolic acidosis.

Prescribing in practice

  • It is a sulfonamide derivative and is contraindicated in sulfonamide hypersensitivity; it can cause electrolyte disturbance, metabolic acidosis and, rarely, serious blood dyscrasias and Stevens-Johnson syndrome.
  • Use with caution and dose adjustment in renal or hepatic impairment, and avoid in marked electrolyte imbalance.
  • Paraesthesia of the extremities and an altered taste of carbonated drinks are common, dose-related effects.

Monitoring

Monitor electrolytes (including potassium) and consider periodic full blood count on prolonged therapy.

Counselling the patient

  • Tingling of the hands and feet and a metallic taste are common and usually harmless.
  • Report a sore throat, fever, rash or unusual bruising.
  • Tell your prescriber if you have any allergy to sulfonamide antibiotics.

Evidence & guidelines

Acetazolamide is a recognised treatment for idiopathic intracranial hypertension and glaucoma in current prescribing references.

Reference: NICE CKS Glaucoma; ABN IIH guideline 2018; SmPC Diamox; Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. The structured dose values shown have been reviewed by a clinician. Monograph status: clinician-reviewed (2026-07-04).

Related

Curated clinical cross-links plus same-class fallbacks.